A multicenter assessment of the ability of preoperative computed tomography scan and serum CA-125 to predict gross residual disease at primary debulking surgery for advanced ovarian, fallopian tube and peritoneal cancer

Suidan, Rudy

21
A multicenter assessment of the ability of preoperative computed tomography scan and serum CA-125 to predict gross residual disease at primary debulking surgery for advanced ovarian, fallopian tube and peritoneal cancer

Sunday, March 29, 2015: 8:28 AM

International Ballroom (Hilton Chicago)

R. S. Suidan¹, P. T. Ramirez², D. Sarasohn¹, J. Teitcher¹, S. Mironov¹, R. Iyer², Q. Zhou¹, J. Denesopolis¹, H. Hricak¹ and D. S. Chi¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²The University of Texas MD Anderson Cancer Center, Houston, TX

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

21
A multicenter assessment of the ability of preoperative computed tomography scan and serum CA-125 to predict gross residual disease at primary debulking surgery for advanced ovarian, fallopian tube and peritoneal cancer

21 A multicenter assessment of the ability of preoperative computed tomography scan and serum CA-125 to predict gross residual disease at primary debulking surgery for advanced ovarian, fallopian tube and peritoneal cancer

21
A multicenter assessment of the ability of preoperative computed tomography scan and serum CA-125 to predict gross residual disease at primary debulking surgery for advanced ovarian, fallopian tube and peritoneal cancer